InvestorsHub Logo
Followers 793
Posts 26336
Boards Moderated 0
Alias Born 09/11/2013

Re: MiamiGent post# 65

Tuesday, 07/14/2020 1:01:11 AM

Tuesday, July 14, 2020 1:01:11 AM

Post# of 145
Right on. The study appeared to have used two groups of patients. I believe the first group was given the drug + supportive care, the second group only got the supportive care. No one in the first group (itolizumab arm) died while about 30% participants in the second group (control arm) sadly passed away.

Very robust outcomes, imo.

$EQ

Disclosure: all Imho only, do your own DD.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent EQ News